Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx)
- PMID: 29873180
- DOI: 10.1111/ajco.13000
Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx)
Abstract
Aim: To validate and compare the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx) for measuring chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients.
Methods: Patients were assessed with the EORTC QLQ-CIPN20, FACT/GOG-Ntx, National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) and World Health Organization criterion of CIPN (WHO-CIPN) from baseline up to 10 assessment points. Internal consistency reliability, convergent validity, discriminant validity and responsiveness of the EORTC QLQ-CIPN20 and FACT/GOG-Ntx were evaluated, respectively. Correlation and regression analysis were used to examine the relationships between these two scales.
Results: Internal reliability coefficients for both scales were above 0.80 across all assessment points. Moderate correlations of the two scales were found with WHO-CIPN (rs = 0.40-0.44; rs = -0.42 to -0.46, all P < 0.05) and NCI-CTCAE (rs = 0.46-0.57; rs = -0.44 to -0.55, all P < 0.01) at most assessment points. Older patients reported significantly more CIPN symptoms than younger counterparts did (P < 0.05). The hypothesized factor structures of both scales were not confirmed (χ2/df = 3.70-7.01; χ2/df = 2.14-10.43, all P < 0.001). Both scales demonstrated responsiveness with small-to-moderate effect size (r = 0.09-0.46, r = 0.11-0.35). The two scales were highly correlated and were predicted by all domains of each other at specific assessment points (R2 = 0.62-0.87; R2 = 0.76-0.85; respectively, all P < 0.001).
Conclusion: The Chinese version of the EORTC QLQ-CIPN20 and FACT/GOG-Ntx demonstrated acceptable reliability, validity and responsiveness and was found comparable in measuring CIPN among Chinese cancer patients at specific assessment points.
Keywords: Chinese; EORTC QLQ-CIPN20; FACT/GOG-Ntx; chemotherapy-induced peripheral neuropathy; psychometrics.
© 2018 John Wiley & Sons Australia, Ltd.
Similar articles
-
Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.Health Qual Life Outcomes. 2020 Jul 23;18(1):246. doi: 10.1186/s12955-020-01493-y. Health Qual Life Outcomes. 2020. PMID: 32703223 Free PMC article.
-
Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.Support Care Cancer. 2019 Dec;27(12):4753-4762. doi: 10.1007/s00520-019-04771-8. Epub 2019 Apr 10. Support Care Cancer. 2019. PMID: 30972646
-
Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.J Natl Compr Canc Netw. 2023 Feb;21(2):125-132.e3. doi: 10.6004/jnccn.2022.7074. J Natl Compr Canc Netw. 2023. PMID: 36791763
-
Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review.Support Care Cancer. 2016 Aug;24(8):3661-8. doi: 10.1007/s00520-016-3270-7. Epub 2016 May 18. Support Care Cancer. 2016. PMID: 27193118 Review.
-
Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.Support Care Cancer. 2018 Apr;26(4):1051-1059. doi: 10.1007/s00520-017-4028-6. Epub 2017 Dec 26. Support Care Cancer. 2018. PMID: 29280005
Cited by
-
Validation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity Questionnaire for the Latin American Population.Int J Breast Cancer. 2022 Sep 10;2022:6533797. doi: 10.1155/2022/6533797. eCollection 2022. Int J Breast Cancer. 2022. PMID: 36124163 Free PMC article.
-
Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time.BMC Cancer. 2019 Nov 27;19(1):1151. doi: 10.1186/s12885-019-6352-3. BMC Cancer. 2019. PMID: 31775665 Free PMC article.
-
Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Treated with Adjuvant or Neo-Adjuvant Chemotherapy.Breast Care (Basel). 2021 Jun;16(3):269-275. doi: 10.1159/000507843. Epub 2020 Jun 16. Breast Care (Basel). 2021. PMID: 34248468 Free PMC article.
-
Peripheral Neuropathy Instruments for Individuals with Cancer: A COSMIN-Based Systematic Review of Measurement Properties.Curr Oncol. 2024 Dec 6;31(12):7828-7851. doi: 10.3390/curroncol31120577. Curr Oncol. 2024. PMID: 39727700 Free PMC article.
-
Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale.World J Gastrointest Oncol. 2020 Feb 15;12(2):205-218. doi: 10.4251/wjgo.v12.i2.205. World J Gastrointest Oncol. 2020. PMID: 32104551 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous